Expression vectors comprising the mCMV IE2 promoter

Details Expression vectors comprising the mCMV IE2 promoter Expression vectors comprising the mCMV IE2 promoter

2004-03-10

2010-11-02

Sajjadi, Fereydoun G (Department: 1633)

Chemistry: molecular biology and microbiology

Vector, per se

C424S093200, C424S199100

Reexamination Certificate

active

07824907

ABSTRACT:
The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV.

REFERENCES:
patent: 4963481 (1990-10-01), deVilliers
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 2004/0076628 (2004-04-01), Chvatchko et al.
patent: 2007/0037734 (2007-02-01), Rossi et al.
patent: 2007/0134761 (2007-06-01), Chatellard et al.
patent: 2007/0196895 (2007-08-01), Aloni et al.
patent: 2007/0293658 (2007-12-01), Kornmann et al.
patent: WO 2004/101617 (2004-11-01), None
patent: WO 2005/040384 (2005-05-01), None
patent: WO 2005/049649 (2005-06-01), None
patent: WO 2005/083058 (2005-09-01), None
patent: WO 2006/003134 (2006-01-01), None
patent: WO 2006/128908 (2006-12-01), None
patent: WO 2006/131550 (2006-12-01), None
Rawlinson et al. (J. Virol. 70:8833-8849; 1996).
Pending claims in U.S. Appl. No. 11/916,087, filed Nov. 30, 2007, not yet published.
Pending claims in U.S. Appl. No. 11/915,453, filed Nov. 26, 2007, not yet published.
Pending claims in U.S. Appl. No. 10/556,417, filed Nov. 10, 2005, not yet published.
Abbate, J. et al. “Bifunctional Protein Conferring Enhanced Green Fluorescence and Puromycin Resistance”Biotechniques,Aug. 2001, pp. 336-340, vol. 31, No. 2.
Assaraf, Y. G. et al. “Characterization of the Coexisting Multiple Mechanisms of Methotrexate Resistance in Mouse 3T6 R50 Fibroblasts*”Journal of Biological Chemistry,Mar. 25, 1992, pp. 5776-5784, vol. 267, No. 9.
Blackwood, E. M. et al. “Going the Distance: A Current View of Enhancer Action”Science,Jul. 3, 1998, pp. 61-63, vol. 281, No. 5373.
DeWet, J. R. et al. “Cloning of Firefly Luciferase cDNA and the Expression of Active Luciferase inEscherichia coli” Proc. Natl. Acad. Sci. USA,1985, pp. 7870-7873, vol. 82.
Dorsch-Hasler, K. et al. “A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus”Proc. Natl. Acad. Sci. USA,Dec. 1985, pp. 8325-8329, vol. 82.
Li, Q. et al. “Locus control regions coming of age at a decade plus”TRENDS In Genetics,Oct. 1999, pp. 403-408, vol. 15, No. 10.
Mazumder, B. et al. “Translational control by the 3′-UTR: the ends specify the means”TRENDS in Biochemical Sciences,Feb. 2003, pp. 91-98, vol. 28, No. 2.
Messerle, M. et al. “Structure and Expression of Murine Cytomegalovirus Immediate-Early Gene 2”Journal of Virology,Mar. 1991, pp. 1638-1643, vol. 65, No. 3.
Kim, S.-Y. et al. “The human elongation factor 1 alpha (EF-1α) first intron highly enhances expression of foreign genes from the murine cytomegalovirus promoter”Journal of Biotechnology,2002, pp. 183-187, vol. 93.
Mountford, P. S. et al. “Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis”TRENDS in Genetics,May 1995, pp. 179-184, vol. 11, No. 5.
Sandford, G. R. et al. “Rat Cytomegalovirus Has a Unique Immediate Early Gene Enhancer”Virology,1996, pp. 310-317, vol. 222.
Schumperli, D. et al. “Efficient Expression ofEscherichia coliGalactokinase Gene in Mammalian Cells”Proc. Natl. Acad. Sci. USA,Jan. 1982, pp. 257-261, vol. 79, No. 2.
Seliger, H. H. et al. “Spectral Emission and Quantum Yield of Firefly Bioluminescence”Archives of Biochemistry and Biophysics,1960, pp. 136-141, vol. 88.
Shotwell, M. A. et al. “Regulation of Amino Acid Transport System L in Chinese Hamster Ovary Cells*”Journal of Biological Chemistry,Mar. 25, 1982, pp. 2974-2980, vol. 257, No. 6.
Wood, K. V. et al. “Synthesis of Active Firefly Luciferase by In Vitro Translation of RNA Obtained from Adult Lanterns”Biochemical and Biophysical Research Communications,Oct. 30, 1984, pp. 592-596, vol. 124, No. 2.
Zhu, W.-Y. et al. “The Rate of Folate Receptor Alpha (FRα) Synthesis in Folate Depleted CHL Cells is Regulated by a Translational Mechanism Sensitive to Media Folate Levels, While Stable Overexpression of its mRNA is Mediated by Gene Amplification and an Increase in Transcript Half-Life”Journal of Cellular Biochemistry,Mar. 26, 2001, pp. 205-219, vol. 81, No. 2.
Baron, U. et al. “Co-regulation of Two Gene Activities by Tetracycline via a Bidrectional Promoter”,Nucleic Acids Research,Sep. 11, 1995, pp. 3605-3606, vol. 23, No. 17.
Manning, W. C. et al. “Insertional Mutagenesis of the Murine Cytomegalovirus Genome: One Prominent α Gene (ie2) is Dispensable for Growth”,Virology,1988, pp. 477-484, vol. 167.
Urabe, M. et al. “A Novel Dicistronic AAV Vector Using a Short IRES Segment Derived from Hepatitis C Virus Genome”,Gene,1997, pp. 157-162, vol. 200.

Affiliated with

Also associated with

Rating

Expression vectors comprising the mCMV IE2 promoter does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Expression vectors comprising the mCMV IE2 promoter, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression vectors comprising the mCMV IE2 promoter will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4170048